You just read:

LabCentral 2018 Impact Report: Resident Companies Raised the Equivalent of 40% of Early Life Sciences VC Funding in Massachusetts and 6% of U.S. Life Sciences IPOs

News provided by

LabCentral

Apr 30, 2019, 09:56 ET